- CFO Spotlights
- Profiles
- Jonathan Gillis
Profile
Jonathan Gillis
interim Chief Financial Officer and interim principal financial officer, MapLight Therapeutics, Inc.
In the seat, on an interim basis. First published here October 28, 2026; built from records as of October 28, 2026.
Jonathan Gillis has been interim Chief Financial Officer and interim principal financial officer of MapLight Therapeutics, Inc. since June 18, 2026, according to the company's filing of June 18, 2026.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) Pharmaceutical Preparations | interim Chief Financial Officer and interim principal financial officer | In the seat, on an interim basis |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- June 18, 2026effective
MapLight Therapeutics, Inc. named Jonathan Gillis interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026. Profile of Vishwas Setia.
Setia, the board of directors of the Company appointed Jonathan Gillis, the Company’s Chief Administrative and Accounting Officer, as the Company’s interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026.
[1] Filing by MapLight Therapeutics, Inc., filed with the SEC on June 18, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, MapLight Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 18, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Jonathan Gillis wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.